Bala
C. Bala, Secunderabad IN
Patent application number | Description | Published |
---|---|---|
20120061967 | OCEAN WATER RUN AND VERTICAL DROP IS GREEN POWER GENERATION - This invention is developed using all the laws of hydraulics and fluid dynamics by digging a tunnel, placing a pipe, etc in the earth surrounding the water body at various levels at least starting from the surface of the water body and going to the very bottom of the water bed in various geometrical figures, angles and degrees suitable for an individual project and individual site and individual generation requirements any where in the world for the water to come out of the water body either from the bottom, below the bottom of the water bed and projecting into the water body or from the sides surrounding the water body and run into the facility from the inlet and various inlets which is constructed below the main level of the water body or mean sea level or main water body level on the earth and required in the water body also so that the various turbine-generators of various capacities, shapes, designs, available in the global markets are erected in a cascading manner or any other system designed for the generation of electricity using various heads and a stable water flow and water velocity in the water ways, The water coming out of the facility with the help of difference in the hydro static pressure etc starting from the water body which is transferred into the tunnel, facility, method etc and the same hydro static pressure is moving in the entire tunnel, facility, system, method etc making the water run and spin the turbines and water is removed with the help of the outlet and multiple outlets exposed to the surface of the earth and open to sky so that the water will flow in the canal which is above the mean sea level discharging the pressure created in the tunnel, facility, method etc by pumps and reaching the water body once again. | 03-15-2012 |
Emrah Bala, Malatya TR
Patent application number | Description | Published |
---|---|---|
20100223565 | METHOD AND SYSTEM FOR PROVIDING AN IMAGE EFFECTS INTERFACE - A method and system for generating user-accessible effects. The method includes receiving a library of operators, each operator including a set of operations performable on an image. The method includes receiving an effect definition from a designer via a graphical user interface, wherein the effect definition includes a set of operators from the library to be executed on a user-provided image and parameters associated with each operator. The method includes saving the effect definition to an accessible memory. The method includes uploading the effect definition to a servers wherein the effect definition is accessible to a user over a network. | 09-02-2010 |
Gezim Bala, Brussel BE
Jan Bala, Pultusk PL
Patent application number | Description | Published |
---|---|---|
20100266453 | PIPETTE WITH ADJUSTABLE VOLUME OF ASPIRATED LIQUID - Pipette with adjustable volume of aspirated liquid built of a handle ( | 10-21-2010 |
20120087846 | PIPETTE WITH ADJUSTABLE VOLUME OF ASPIRATED LIQUID - Pipette with adjustable volume of aspirated liquid built of a handle ( | 04-12-2012 |
20140086807 | PIPETTE FOR USE WITH A PIPETTE TIP - A pipette ( | 03-27-2014 |
Jan Adam Bala, Pultusk PL
Patent application number | Description | Published |
---|---|---|
20120148459 | MECHANICAL PIPETTE WITH ADJUSTABLE VOLUME VALUE OF ASPIRATED LIQUID - Mechanical pipette with adjustable volume value of aspirated liquid is built of a handle ( | 06-14-2012 |
Kamlesh Bala, Horsham GB
Patent application number | Description | Published |
---|---|---|
20140135329 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 05-15-2014 |
20150045364 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 02-12-2015 |
Kamlesh Jagdis Bala, West Sussex GB
Patent application number | Description | Published |
---|---|---|
20080200466 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions - Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R | 08-21-2008 |
20090082365 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists - The present invention relates to quinazolinone compounds of the formula | 03-26-2009 |
20090209552 | Organic Compounds - There are provided according to the invention compounds of formula (I) | 08-20-2009 |
Kamlesh Jagdis Bala, Horsham GB
Patent application number | Description | Published |
---|---|---|
20100204225 | Organic compounds - There are provided according to the invention compounds of formula (I), in free or salt form, wherein R | 08-12-2010 |
20100210610 | Organic compounds - There are provided according to the invention compounds of formula (I), in free or salt form, wherein R | 08-19-2010 |
20110230483 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 09-22-2011 |
20120277232 | Pyridine and Pyrazine Derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 11-01-2012 |
20130267518 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS - There are provided according to the invention compounds of formula (I) | 10-10-2013 |
20140309254 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS - There are provided according to the invention compounds of formula (I) | 10-16-2014 |
20150329529 | CARBOXAMIDE DERIVATIVES - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; | 11-19-2015 |
Kamlesh Jagdis Bala, Horsham, Sussex UK
Patent application number | Description | Published |
---|---|---|
20140323485 | N-Substituted Heterocyclyl Carboxamides - A compound of Formula I | 10-30-2014 |
Kason Bala, Reading GB
Patent application number | Description | Published |
---|---|---|
20090005519 | Supramolecular Polymers - The invention concerns novel cytosine based modules and in particular their application in linear multiple hydrogen bonded arrays to form supramolecular polymers of the formula (II): and the use of these in supramolecular materials. | 01-01-2009 |
Kason Bala, Winchester GB
Patent application number | Description | Published |
---|---|---|
20090299067 | New synthesis of 2,6-diamino-3,5-dinitropyrazine-1-oxide from 2,6-diaminopyrazine-1-oxide - A method for the synthesis of 2,6-Diamino-3,5-dinitropyrazine-1-oxide including nitration of 2,6-diaminopyrazine-1-oxide. The step of nitration may use nitrating agents 20% Oleum/100% HNO3, 100% HNO3 and conc. H2504/100% HNO3 or nitronium tetrfluoraoborate. The synthesis of 2,6-diaminopyrazine-1-oxide may involve both the oxidation of 2,6-diaminopyrazine, the amination of a precursor 2,6-disubstitutedpyrazine-1-oxide or direct formation of the 2,6-diaminopyrazine-l-oxide from the precursor, 2-amino-6-hydroxamino-pyrazine-1-oxide. | 12-03-2009 |
Phalguni Bala, West Bengal IN
Patent application number | Description | Published |
---|---|---|
20110062983 | REDUCING SWITCHING NOISE - Described herein are various principles for operating a transmitter circuit to reduce noise affecting a signal being generated and reducing jitter. In some embodiments, a circuit is operated in a way that switching occurs at or above a bit rate of transmission, such that at least one switch changes state at least for every bit. Operating the circuit in such a way leads to a switching rate that is above a resonant frequency of the circuit and prevents large oscillations and noise from being inserted into the signal and causing communication problems. | 03-17-2011 |
Ramachandran Koduvayur Bala, Tirupati IN
Patent application number | Description | Published |
---|---|---|
20140257838 | Patient Care plan determination - Patient characteristics as well as cost and quality measures may be used to determine a suitable care plan for a patient having a particular medical condition from a collection of care plans. The patient characteristics may be used to initially filter the care plans to meet basic topical characteristics of the patient such as gender or age. Care plans may be further filtered based on other characteristics such as insurance applicability, performance measures, and cost characteristics of specific care plans. Care plans passing through the various filters may be provided to a user such that pertinent information such as cost, frequency, and effectiveness of care for each filtered plan may be displayed. A user then may have sufficient information available to select an appropriate care plan for the specific patient. | 09-11-2014 |